Literature DB >> 15225190

Ovarian stimulation for in vitro fertilization in patients with endometriosis.

Kostantinos Zikopoulos1, Efstratios M Kolibianakis, Paul Devroey.   

Abstract

The use of gonadotropin-releasing hormone (GnRH) agonists in a long protocol appears to enhance the probability of conception in the presence of endometriosis. In addition, there is evidence to suggest that the use of prolonged downregulation with GnRH agonists prior to ovarian stimulation for in vitro fertilization (IVF) is beneficial for achieving pregnancy. Until now, GnRH antagonists have not been used in patients with endometriosis. The management of endometriomas prior to stimulation for IVF and its impact on reproductive outcome are still subject to debate.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15225190     DOI: 10.1111/j.0001-6349.2004.00543.x

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  3 in total

1.  Mild starting dosage ovarian stimulation combined with a modified prolonged GnRH-a protocol improved IVF/ICSI outcomes in normal ovarian responders.

Authors:  Li-Feng Tian; Jun Tan; Yang Zou; Qiong Su; You Li; Ding-Fei Xu; Qiong-Fang Wu
Journal:  Arch Med Sci       Date:  2019-05-16       Impact factor: 3.318

2.  The follicular-phase depot GnRH agonist protocol results in a higher live birth rate without discernible differences in luteal function and child health versus the daily mid-luteal GnRH agonist protocol: a single-centre, retrospective, propensity score matched cohort study.

Authors:  Ying Zhang; Wenxian Zhao; Yifan Han; Xin Chen; Shaoyuan Xu; Yueyue Hu; Honglu Diao; Changjun Zhang
Journal:  Reprod Biol Endocrinol       Date:  2022-09-19       Impact factor: 4.982

3.  Comparison of GnRH-a Prolonged Protocol and Short GnRH-a Long Protocol in Patients with Thin Endometrium for Assisted Reproduction: A Retrospective Cohort Study.

Authors:  Jianyuan Song; Cuicui Duan; Wangyu Cai; Wei Wu; Houyi Lv; Jian Xu
Journal:  Drug Des Devel Ther       Date:  2020-09-11       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.